On December 14, 2020, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Fuzuloparib Capsules (brand name: Airuiyi), a Class 1 innovative drug developed by Jiangsu Hengrui Pharmaceutical Co., Ltd., via the priority review and approval procedure. As an innovative drug independently researched and developed in China with independent intellectual property rights, Fuzuloparib is indicated for the treatment of patients with platinum‑sensitive recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer associated with germline BRCA mutation (gBRCAm) who have received two or more lines of prior chemotherapy.
Fuzuloparib is a small‑molecule poly(ADP‑ribose) polymerase (PARP) inhibitor. It inhibits the DNA repair process in cells with dysfunctional BRCA1/2, induces cell cycle arrest, and thereby suppresses tumor cell proliferation. The approval of this product provides a new therapeutic option for patients.
